PatentsIndia
Calcutta High Court Reverses Rejection of Pharmacyclics’ Divisional Patent on Ibrutinib Combination Therapy
The Calcutta High Court has set aside the Indian Patent Office’s rejection of Pharmacyclics LLC’s divisional patent application covering a combination therapy of ibrutinib with anti-CD20 antibodies for hematological malignancies. The ruling affirms that divisional applications are maintainable when supported by the pa…
Wednesday, September 10, 2025